Nasdaq:RYTM

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…

1 week ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025 16:16 ET  | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…

2 weeks ago